Search results for "Streptokinase"

showing 9 items of 9 documents

Pharmacological thrombolysis: one more weapon for free-flap salvage.

2005

Despite the high success rate of free-tissue transfer, thrombosis still complicates 5-30% of cases. Meticoulous technique, careful vessel selection, and pharmacological prophylaxis are not always enough to avoid thrombosis. Early diagnosis and reintervention provide the only way to salvage a thrombosed free flap, in case of either arterial or venous thrombosis. When kinking, torsion, or external compression of the pedicle are ruled out, and thrombectomy and redo of the anastomosis are unsuccessful, the last resort to save the flap is thrombolytic therapy. The authors present their experience with the salvage of two otherwise lost flaps by means of urokinase thrombolysis through direct intra…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentFree flapAnastomosisTHERAPYSurgical FlapsMICROVASCULAR SURGERYFibrinolysismedicineMANAGEMENTHumansThrombolytic TherapyVeinUrokinaseAged 80 and overVenous Thrombosisbusiness.industrySTREPTOKINASE SALVAGEGraft SurvivalThrombolysisTHROMBECTOMYmedicine.diseaseThrombosisUrokinase-Type Plasminogen ActivatorSurgeryVenous thrombosismedicine.anatomical_structureSurgerybusinessmedicine.drugMicrosurgery
researchProduct

In vitro Analysis of Synergistic Effects of Fibrinolytic Agents and Prostacyclin Analogues

1997

We investigated the in vitro thrombolytic effects of streptoki-nase, urokinase, alteplase and saruplase, alone or in combination, with the prostacyclin analogues, iloprost and taprostene. Human platelet-rich plasma was stimulated with collagen (1 μg/ml) to generate thrombi containing platelets and fibrin. Following treatment with fibrinolytic agents, lysis was allowed to proceed for 30 min and was then terminated with aprotinin (2,000 ClU/ml). To evaluate the combinatory effects of fibrinolytic agents and prostacyclin analogues, we used concentrations of fibrinolytic agents which reduced thrombi weight by less than 50%. Neither iloprost nor taprostene alone demonstrated any thrombolytic eff…

AdultMalemedicine.medical_treatmentProstacyclinPharmacologyFibrinolytic AgentsPhysiology (medical)Prostaglandins SyntheticFibrinolysismedicineHumansStreptokinaseIloprostUrokinaseChemistryFibrinolysisDrug SynergismHematologyDrug interactionEpoprostenolUrokinase-Type Plasminogen ActivatorIn vitroTissue Plasminogen Activatorcardiovascular systemFemaleSaruplaseFibrinolytic agentIloprostmedicine.drugPathophysiology of Haemostasis and Thrombosis
researchProduct

Evaluation of post-myocardial infarction regional and global left ventricular function by monoplane ventriculography: superiority of right versus lef…

1996

OBJECTIVES To study the significance of serial quantitative regional wall motion analysis, volumes, and ejection fraction findings as well as their prognostic implications derived from cineventriculography in 30 degrees right anterior oblique (RAO) projection in comparison with 60 degrees left anterior oblique (LAO) projection in post-myocardial infarction patients. Ventriculographic left ventricular parameters are accepted surrogates of mortality in myocardial infarction. Nowadays, in contrast to a biplanar approach in most institutions and clinical trials, the investigation is reduced to monoplanar ventriculography. However, it is not known whether the relevance of the two established pro…

Malemedicine.medical_specialtyStreptokinaseMyocardial InfarctionInfarctionPost myocardial infarctionVentricular Function LeftInternal medicineMedicineHumansMyocardial infarctionAngioplasty Balloon CoronaryVentricular remodelingProjection (set theory)Ejection fractionbusiness.industryGated Blood-Pool ImagingStroke VolumeGeneral MedicineMiddle Agedmedicine.diseaseThrombosisSurvival AnalysisEvaluation Studies as TopicCardiologyFemaleCardiology and Cardiovascular Medicinebusinessmedicine.drugCoronary artery disease
researchProduct

Thrombolysis with saruplase versus streptokinase in acute myocardial infarction: five-year results of the PRIMI trial.

1999

Abstract Background Short-term safety and efficacy of thrombolysis with saruplase in acute myocardial infarction have been shown in several trials. To assess long-term outcome of patients treated with saruplase or streptokinase for myocardial infarction, a 5-year follow-up of patients included in the Pro-Urokinase in Myocardial Infarction Trial was performed. Methods and Results Follow-up data are available from 8 centers on 255 (92.4%) of 276 included patients. The 5-year mortality rate was comparable with 20.8% of patients in the saruplase group and 16.9% in the streptokinase group (odds ratio 1.29, 95% confidence interval 0.69 to 2.42). In both groups, a considerable number of fatal card…

Malemedicine.medical_specialtyStreptokinasemedicine.medical_treatmentMyocardial InfarctionAnginaCohort StudiesFibrinolytic AgentsRecurrenceAngioplastyInternal medicineMedicineHumansStreptokinaseThrombolytic TherapyMyocardial infarctionAngioplasty Balloon CoronaryCoronary Artery BypassAgedbusiness.industryOdds ratioThrombolysisMiddle Agedmedicine.diseaseSurvival AnalysisUrokinase-Type Plasminogen ActivatorConfidence intervalRecombinant ProteinsCerebrovascular DisordersCardiologySaruplaseFemaleCardiology and Cardiovascular Medicinebusinessmedicine.drugFollow-Up StudiesAmerican heart journal
researchProduct

Combined medical and mechanical recanalization in acute myocardial infarction

1985

A technique of combined medical and mechanical recanalization was employed in 96 patients with acute transmural myocardial infarction. The mean time between onset of symptoms and admission to hospital was 170 +/- 65 min (X +/- SD). After 10 +/- 16 min, 250,000 U streptokinase was administered intravenously for 20 min. Intracoronary thrombolysis was commenced within 38 +/- 14 min. First coronary angiograms demonstrated reperfusion, an open vessel in 25/96 patients (26%). In 15/71 patients (21%) reperfusion occurred during thrombolysis therapy, before mechanical recanalization could be performed. Recanalization was achieved mechanically in 37/71 patients (52%) with occluded coronary vessels. …

Malemedicine.medical_specialtymedicine.medical_treatmentStreptokinaseMyocardial InfarctionCoronary DiseaseAnterior myocardial infarctionElectrocardiographyRecurrenceCoronary CirculationInternal medicinemedicineHumansInfusions ParenteralStreptokinaseMyocardial infarctionAgedChemotherapybusiness.industryHemodynamicsArrhythmias CardiacStroke VolumeThrombolysisMiddle Agedmedicine.diseaseCombined Modality TherapyMyocardial ContractionPeripheralCoronary vesselCardiologyFemaleCardiology and Cardiovascular MedicinebusinessAngioplasty Balloonmedicine.drugIntracoronary thrombolysisCatheterization and Cardiovascular Diagnosis
researchProduct

Molecular Co-operation between Protein PAM and Streptokinase for Plasmin Acquisition by Streptococcus pyogenes

1998

Bacterial surface-associated plasmin formation is believed to contribute to invasion, although the underlying molecular mechanisms are poorly understood. To define the components necessary for plasmin generation on group A streptococci we used strain AP53 which exposes an M-like protein ("PAM") that contains a plasminogen-binding sequence with two 13-amino acid residues long tandem repeats (a1 and a2). Utilizing an Escherichia coli-streptococcal shuttle vector, we replaced a 29-residue long sequence segment of Arp4, an M-like protein that does not bind plasminogen, with a single (a1) or the combined a1a2 repeats of PAM. When expressed in E. coli, the purified chimeric Arp/PAM proteins both …

Streptococcus pyogenesPlasminRecombinant Fusion Proteinsmedicine.medical_treatmentStreptokinasemedicine.disease_causeBiochemistryMicrobiologyBacterial Proteinsstomatognathic systemShuttle vectorTandem repeatEscherichiaparasitic diseasesmedicineStreptokinaseFibrinolysinMolecular BiologyGeneAntigens BacterialProteasebiologyPlasminogenCell Biologybiology.organism_classificationBiochemistryStreptococcus pyogenesTransformation BacterialCarrier ProteinsBacterial Outer Membrane Proteinsmedicine.drugJournal of Biological Chemistry
researchProduct

Abciximab Facilitates the Rate and Extent of Thrombolysis

1999

Background —The TIMI 14 trial tested the hypothesis that abciximab, the Fab fragment of a monoclonal antibody directed to the platelet glycoprotein (GP) IIb/IIIa receptor, is a potent and safe addition to reduced-dose thrombolytic regimens for ST-segment elevation MI. Methods and Results —Patients (n=888) with ST-elevation MI presenting <12 hours from onset of symptoms were treated with aspirin and randomized initially to either 100 mg of accelerated-dose alteplase (control) or abciximab (bolus 0.25 mg/kg and 12-hour infusion of 0.125 μg · kg −1 · min −1 ) alone or in combination with reduced doses of alteplase (20 to 65 mg) or streptokinase (500 000 U to 1.5 MU). Control patients recei…

business.industrymedicine.medical_treatmentStreptokinaseReteplaseThrombolysismedicine.diseaseBolus (medicine)Physiology (medical)AnesthesiamedicineAbciximabPlatelet aggregation inhibitorMyocardial infarctionCardiology and Cardiovascular MedicinebusinessTIMImedicine.drugCirculation
researchProduct

Residual coronary stenosis after thrombolysis with rt-PA or streptokinase: acute results and 3 weeks follow-up

1987

Ninety-one patients with acute myocardial infarction were assigned to intravenous treatment with streptokinase or rt-PA as part of the randomized trial carried out by the European Study Group for Recombinant Tissue-Type Plasminogen Activator (rt-PA). A patent coronary artery was found in 37 of 45 (82%) patients treated with rt-PA and in 27 of 46 (59%) patients treated with streptokinase 75-90 minutes after start of infusion. Patients were subsequently anticoagulated with heparin or dicoumarol up to a repeat angiography 3 weeks after the infarction. Of the 64 patients with successful reperfusion, 3 died and 3 suffered reocclusion of the vessel. Quantitative analysis of the coronary stenosis …

medicine.medical_specialtymedicine.medical_treatmentStreptokinaseInfarctionCoronary DiseaseCoronary AngiographyRandom AllocationReperfusion therapyRecurrenceInternal medicineHumansMedicineStreptokinaseMyocardial infarctionVascular PatencyClinical Trials as Topicmedicine.diagnostic_testbusiness.industryHeparinThrombolysisMiddle Agedmedicine.diseaseRecombinant Proteinsmedicine.anatomical_structureTissue Plasminogen ActivatorAngiographyCardiologyCineangiographyRadiographic Image Interpretation Computer-AssistedCardiology and Cardiovascular MedicinebusinessFollow-Up Studiesmedicine.drugArteryEuropean Heart Journal
researchProduct

Thrombolytic therapy for submassive pulmonary embolism.

2012

Approximately 10% of all patients with acute pulmonary embolism (PE) die within the first three months after diagnosis. However, PE is not universally life-threatening, but covers a wide spectrum of clinical severity and death risk. Thrombolytic treatment is indicated patients with acute massive PE who are at high risk for early death, i.e. those patients who present with arterial hypotension and shock. On the other hand, low molecular-weight heparin or fondaparinux is adequate treatment for most normotensive patients with PE. Recombinant tissue plasminogen activator, given as 100 mg infusion over 2 h, is the treatment of choice for patients with PE, although older regimens using urokinase …

medicine.medical_specialtymedicine.medical_treatmentStreptokinaseVentricular Dysfunction RightClinical Biochemistry030204 cardiovascular system & hematologyFondaparinuxlaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled trialFibrinolytic AgentslawPolysaccharidesRisk FactorsInternal medicinemedicineHumansStreptokinaseThrombolytic Therapy030212 general & internal medicineIntensive care medicineUrokinaseClinical Trials as Topicbusiness.industryHeparinThrombolysisHeparin Low-Molecular-Weightmedicine.diseaseUrokinase-Type Plasminogen ActivatorTroponin3. Good healthPulmonary embolismRadiographyOncologyFondaparinuxTissue Plasminogen ActivatorAcute DiseaseCardiologybusinessPulmonary EmbolismBiomarkersmedicine.drugCohort studyBest practiceresearch. Clinical haematology
researchProduct